Literature DB >> 33159436

Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders.

Dorina Ylli1,2, Leonard Wartofsky1, Kenneth D Burman1.   

Abstract

Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. Deiodination of amiodarone releases large amounts of iodine that can impair thyroid function, causing either hypothyroidism or thyrotoxicosis in susceptible individuals reflecting ~20% of patients administered the drug. Not only the excess iodine, but also the amiodarone (or its metabolite, desethylamiodarone) itself may cause thyroid dysfunction by direct cytotoxicity on thyroid cells. We present an overview of the epidemiology and pathophysiology of amiodarone-induced thyroid disorders, with a focus on the various forms of clinical presentation and recommendations for personalized management of each form.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  amiodarone; hypothyroidism; management; thyroid; thyroiditis; thyrotoxicosis

Year:  2021        PMID: 33159436     DOI: 10.1210/clinem/dgaa686

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  A Refractory Case of Amiodarone Thyrotoxicosis.

Authors:  Marta Fonseca; Mário Ferreira; Joana Paulo; Zélia Neves
Journal:  Cureus       Date:  2022-08-29

Review 2.  Iodine as a potential endocrine disruptor-a role of oxidative stress.

Authors:  Małgorzata Karbownik-Lewińska; Jan Stępniak; Paulina Iwan; Andrzej Lewiński
Journal:  Endocrine       Date:  2022-06-20       Impact factor: 3.925

3.  Protective Role of Amiodarone on Reperfusion Arrhythmia in Patients of Acute Myocardial Infarction with Percutaneous Coronary Intervention Treatment.

Authors:  Jianying Wang; Jinchang Leng; Xiaowei Sun; Kun Peng; Xaojuan Ma; Shiqin Huang; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-26       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.